Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH

NCT02894008 is registered in ClinicalTrials.gov with University of York as lead sponsor.

NCT NCT02894008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02894008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH
Lead sponsor
University of York
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
December 31, 2019
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leishmaniasis, cutaneous